ASH: Complications Common With Controlled Ovarian Hyperstimulation in Sickle Cell Anemia
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 14, 2024 -- Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation (OC) have complications, according to a study scheduled for presentation at the annual meeting of the American Society of Hematology, to be held from Dec. 9 to 12 in San Diego.
Marti Goldenberg, D.O., from Johns Hopkins Hospital in Baltimore, and colleagues described clinical factors associated with oocyte recovery and COH complications in sickle cell anemia in a five-center retrospective study. Participants had sickle cell disease and an attempt at OC; all 46 participants had sickle cell anemia.
The researchers found that 44 of the participants underwent fertility preservation before curative therapy; one had diminished ovarian reserve, and one had in vitro fertilization with preimplantation genetic testing. Insurance was private, public, self-pay, or research protocol (15, nine, six, or 15, respectively). The median number of acute care visits for pain was four in the year before OC. Overall, there were 55 COH cycles, which were performed in ambulatory or operating room settings (33 and 18, respectively). Thirty-six individuals underwent one COH cycle. Due to poor ovarian response, three cycles were canceled. Six participants required multiple cycles for low oocyte yield or cycle cancellation (five and one, respectively). Complications occurred in 25 cycles; 11 individuals had more than one complication. There was an association for any OC complication with three or more vasculo-occlusive episodes (VOE) in the year prior to COH.
"Complications were common and ≥3 VOE in the year before COH predicted pain following COH, underscoring the need for individualized pain plans before COH," the authors write.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Hydroxyurea Has Sustained Clinical Benefits in Children With Sickle Cell Anemia
TUESDAY, April 29, 2025 -- For children with sickle cell anemia (SCA), hydroxyurea has sustained clinical benefits in terms of reducing emergency department visits and hospital...
C-Reactive Protein Increases During Menstrual Cycle in Females With Sickle Cell Disease
TUESDAY, April 15, 2025 -- For adults with sickle cell disease (SCD), C-reactive protein (CRP) levels increase significantly during the follicular phase of the menstrual cycle...
Recommendations Updated for Fertility Preservation in Cancer
THURSDAY, April 10, 2025 -- In a special article published online March 19 in the Journal of Clinical Oncology, the American Society of Clinical Oncology presents updated...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.